Association of Plasma Amylin Concentration With Alzheimer Disease and Brain Structure in Older Adults.

ABSTRACT: Importance:Preclinical studies suggest that amylin has a U-shaped dose-response association with risk of Alzheimer disease (AD). The association of plasma amylin with AD in humans is unknown. Objectives:To measure amylin concentration in plasma by using enzyme-linked immunosorbent assay and to study the association between plasma amylin, incidence of AD, and brain structure in humans. Design, Setting, and Participants:This cohort study used data from the Framingham Heart Study offspring cohort from 1998 to 2015. Using a Monte Carlo approach, participants were divided into 3 plasma amylin concentration groups: (1) low (<75 pmol/L), (2) high (75-2800 pmol/L), and (3) extremely high (?2800 pmol/L). Data analyses were conducted October 5, 2017, to December 18, 2018. Exposures:Baseline plasma amylin concentrations at examination 7. Main Outcomes and Measures:Incidence of dementia or AD and brain volumetric measures from structural magnetic resonance imaging data. Results:From the Framingham Heart Study offspring cohort, 3061 participants (mean [SD] age at baseline, 61.0 [9.5] years; 1653 [54.0%] women) who had plasma amylin measurements, dementia incidence, and brain volume measurements on record were included in this study. The distribution of plasma amylin concentrations was highly skewed (median [interquartile range], 7.5 [4.6-18.9] pmol/L; mean [SD], 302.3 [1941.0] pmol/L; range, 0.03-44?623.7 pmol/L). Compared with the low plasma amylin concentration group, the high plasma amylin concentration group had a lower rate of AD incidence (2.3% vs 5.6%; P?=?.04), but the extremely high plasma amylin concentration group had a higher rate of AD incidence (14.3%; P?

SUBMITTER: Zhu H 

PROVIDER: S-EPMC6707010 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature